Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Journal of Thrombosis and Thrombolysis
Erschienen in: Journal of Thrombosis and Thrombolysis 3/2014

01.04.2014

Novel oral anticoagulants: pharmacology, coagulation measures, and considerations for reversal

verfasst von: Larry R. Jackson II, Richard C. Becker

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Novel oral anticoagulants (NOAC) provide an effective and, in some cases, superior alternative to traditional, oral vitamin K antagonists such as warfarin. These drugs differ in their pharmacokinetic and pharmacodynamics profiles, which is important for selecting the right drug for the right patient. A concern among clinicians is a virtual absence of guidance from clinical trials for reversing the anticoagulant effects of these drugs in clinical settings such as life-threatening bleeding or a need for emergent procedures that carry bleeding risk. In this review, we discuss NOAC, the role of coagulation assays to assess their systemic anticoagulants effects, and the available data supporting strategies designed to reverse or attenuate these effects.
Literatur
1.
Zehnder J, Katzung SM, Trevor A (2009) Basic and clinical pharmacology, 11th edn. McGraw-Hill Medical, New York
2.
3.
Sanderson S, Emery J, Higgins J (2005) CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 7:97–104PubMedCrossRef
4.
Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151PubMedCrossRef
5.
Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W (2008) The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 36:386–399PubMedCrossRef
6.
Schulman S, Kearon C, Kakkar AK et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361:2342–2352PubMedCrossRef
7.
Pharm. BI (2011) PRADAXA (dabigatran etexilate): reducing risk of stroke from atrial fibrillation (Afib). Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT
8.
Ordovás Baines JP, Climent Grana E, Jover Botella A, Valero Garcia I (2009) Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban. Farm Hosp 33:125–133PubMedCrossRef
9.
Hankey GJ, Eikelboom JW (2011) Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 123:1436–1450PubMedCrossRef
10.
Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891PubMedCrossRef
11.
AG BSP (2011) Xarelto: summary of product characteristics. Bayer Pharma AG, Berlin
12.
Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G (2005) Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 78:412–421PubMedCrossRef
13.
Fareed J, Thethi I, Hoppensteadt D (2012) Old versus new oral anticoagulants: focus on pharmacology. Annu Rev Pharmacol Toxicol 52:79–99PubMedCrossRef
14.
Granger CB, Alexander JH, McMurray JJ et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992PubMedCrossRef
15.
Carreiro J, Ansell J (2008) Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict. Expert Opin Investig Drugs 17:1937–1945PubMedCrossRef
16.
Zafar MU, Vorchheimer DA, Gaztanaga J et al (2007) Antithrombotic effects of factor Xa inhibition with DU-176b: phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost 98:883–888PubMed
17.
Favaloro EJ, Lippi G (2012) The new oral anticoagulants and the future of haemostasis laboratory testing. Biochemia medica : casopis Hrvatskoga drustva medicinskih biokemicara / HDMB 22:329–341CrossRef
18.
Ng VL (2009) Prothrombin time and partial thromboplastin time assay considerations. Clin Lab Med 29:253–263PubMedCrossRef
19.
20.
Miyares MA, Davis K (2012) Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient. Am J Health Syst Pharm 69:1473–1484PubMedCrossRef
21.
Tripodi A, van den Besselaar A (2009) Laboratory monitoring of anticoagulation: where do we stand? Semin Thromb Hemost 35:34–41PubMedCrossRef
22.
Asmis LM, Alberio L, Angelillo-Scherrer A et al (2012) Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories. Thromb Res 129:492–498PubMedCrossRef
23.
Becker RC, Yang H, Barrett Y et al (2011) Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban–an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis 32:183–187PubMedCrossRef
24.
Castellone DD, Van Cott EM (2010) Laboratory monitoring of new anticoagulants. Am J Hematol 85:185–187PubMedCrossRef
25.
Colomina MJ, Diez Lobo A, Garutti I, Gomez-Luque A, Llau JV, Pita E (2012) Perioperative use of prothrombin complex concentrates. Minerva Anestesiol 78:358–368PubMed
26.
Dentali F, Marchesi C, Pierfranceschi MG et al (2011) Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists: a meta-analysis. Thromb Haemost 106:429–438PubMedCrossRef
27.
Hsia CC, Chin-Yee IH, McAlister VC (2008) Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials. Ann Surg 248:61–68PubMedCrossRef
28.
Hardy JF, Belisle S, Van der Linden P (2008) Efficacy and safety of recombinant activated factor VII to control bleeding in nonhemophiliac patients: a review of 17 randomized controlled trials. Ann Thorac Surg 86:1038–1048PubMedCrossRef
29.
Girolami A, Ruzzon E, Tezza F, Scandellari R, Vettore S, Girolami B (2006) Arterial and venous thrombosis in rare congenital bleeding disorders: a critical review. Haemophilia 12:345–351PubMedCrossRef
30.
van Ryn J, Stangier J, Haertter S et al (2010) Dabigatran etexilate–a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103:1116–1127PubMedCrossRef
31.
Holbrook A, Schulman S, Witt DM et al (2012) Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e152S–e184SPubMedCentralPubMedCrossRef
32.
Lubetsky A, Yonath H, Olchovsky D, Loebstein R, Halkin H, Ezra D (2003) Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med 163:2469–2473PubMedCrossRef
33.
Fredriksson K, Norrving B, Stromblad LG (1992) Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke 23:972–977PubMedCrossRef
34.
Freeman WD, Brott TG, Barrett KM et al (2004) Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc 79:1495–1500PubMedCrossRef
35.
Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G (2012) Oral anticoagulant therapy: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e44S–e88SPubMedCentralPubMedCrossRef
36.
Samama MM, Guinet C (2011) Laboratory assessment of new anticoagulants. Clin Chem Lab Med 49:761–772PubMedCrossRef
37.
Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124:1573–1579PubMedCrossRef
38.
Chan HHW, Atkinson HM, Goncharenko M, Berry LR, Chan AKC (2011) Reversal of dabigatran using recombinant activated factor VII and activated prothrombin complex concentrates in thromboelastography assay. J Thromb Haemost 9:576–577 (Abstracts of the XXIII Congress of the International Society on Thrombosis and Haemostasis, 57th Annual SSC Meeting, 2011)
39.
Zhou W, Schwarting S, Illanes S et al (2011) Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 42:3594–3599PubMedCrossRef
40.
Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G (2012) Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 108:217–224PubMedCrossRef
41.
Siegal DM, Crowther MA (2013) Acute management of bleeding in patients on novel oral anticoagulants. Eur Heart J 34:489–498PubMedCrossRef
42.
Escolar G, Arellano-Rodrigo E, Reverter JC et al (2012) Reversal of apixaban induced alterations of hemostasis by different coagulation factor concentrates: studies in vitro with circulating human blood. Circulation 126(4):520–521 (Abstract from the Emerging Science Series)
43.
Fukuda T, Honda Y, Kamisato C, Morishima Y, Shibano T (2012) Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Haemost 107:253–259PubMedCrossRef
44.
Morishima Y, Honda Y, Kamisato C, Furugohri T, Shibano T (2011) Reversal agents for edoxaban, a factor Xa inhibitor: effects of factor VIIa, anti-inhibitor coagulant complex, prothrombin complex concentrate, fresh plasma, and vitamin K. J Thromb Haemost 9:135
45.
Lu GP, Luan P, Hollenbach S, Abe K, DeGuzman F, Siu G, Hutchaleelaha A, Inagaki M, Conley PB, Phillips DR, Sinha U (2009) Reconstructed recombinant factor Xa as an antidote to reverse anticoagulation by factor Xa inhibitors. J Thromb Haemost 7:309 (Abstracts of the XXIII Congress of the International Society on Thrombosis and Haemostasis, 57th Annual SSC Meeting, 2011)
46.
Van Ryn J, Litzenburger T, Waterman A (2011) CanadaK, Hauel N, Kroe-Barrett R, Singh S, Park J. Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran in in vitro and in vivo models. J Am Coll Cardiol 57:E1130CrossRef
Metadaten
Titel
Novel oral anticoagulants: pharmacology, coagulation measures, and considerations for reversal
verfasst von
Larry R. Jackson II
Richard C. Becker
Publikationsdatum
01.04.2014
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 3/2014
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-013-0958-0

Weitere Artikel der Ausgabe 3/2014

Journal of Thrombosis and Thrombolysis 3/2014 Zur Ausgabe

OriginalPaper

Clinical features in patients with pulmonary embolism at a community hospital: analysis of 4 years of data

OriginalPaper

Platelet distribution width and the risk of periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention

OriginalPaper

Pulmonary embolism in pregnancy

Report

Lemierre’s syndrome: the forgotten disease

Letter to the Editor

Use of ticagrelor in patients with ST-elevation myocardial infarction undergoing thrombolysis

ReviewPaper

Antiplatelet therapy in prevention of cardio- and venous thromboembolic events

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Ist Fasten vor Koronarinterventionen wirklich nötig?

04.06.2024 Interventionelle Verfahren in der Kardiologie Nachrichten

Wenn Eingriffe wie eine Koronarangiografie oder eine Koronarangioplastie anstehen, wird häufig empfohlen, in den Stunden zuvor nüchtern zu bleiben. Ein französisches Forscherteam hat diese Maßnahme hinterfragt.

Typ-2-Diabetes: Ernährungsunsicherheit vervierfacht Risiko für schwere Hypoglykämien

04.06.2024 Typ-2-Diabetes Nachrichten

Wenn ältere Menschen mit Typ-2-Diabetes Schwierigkeiten beim Beschaffen und Zubereiten von Mahlzeiten haben, geht dies mit einem deutlich gesteigerten Risiko für schwere Hypoglykämien einher.

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

04.06.2024 Levonorgestrel Nachrichten

Unter Frauen, die ein Levonorgestrel-freisetzendes intrauterines System (IUS) verwenden, ist die Brustkrebsrate um 13% erhöht. Dafür kommt es deutlich seltener zu Endometrium-, Zervix- und Ovarialkarzinomen.

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

03.06.2024 Semaglutid Nachrichten

Der GLP-1-Agonist Semaglutid hat in der FLOW-Studie bewiesen, dass sich damit die Progression chronischer Nierenerkrankungen bei Patienten mit Typ-2-Diabetes bremsen lässt. Auch in kardiovaskulärer Hinsicht war die Therapie erfolgreich.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise